|
Sorted by: Date | Top Results
|
|
Author |
|
Date |
| |
| |
| 1. |
I finally got thru to IR today and was told "no comment" to my question(s) 
regarding the Jeffries & Co. analysis by Ed Liston.
To me that means that there is surely "fire where
there is smoke", and I have sold all 22,000 shares
of amln I have...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Amylin Pharmaceuticals, Inc.
|
|
warrsurplus |
|
19-Jan-10 12:37 pm |
| |
| 2. |
I can&&39;t help it, but with this latest from amln (if its true)
is going to force me to sell all my shares. I've
been long amln for over twelve years and have always
been a staunch defended of amln's work, management
and innovative...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Amylin Pharmaceuticals, Inc.
|
|
warrsurplus |
|
17-Jan-10 12:04 am |
| |
| 3. |
Without a doubt, the reason for today&&39;s plunge is that amln will
have to go in front of an advisory committee for LAR.
That means that LAR will most certainly not be approved
anytime soon, i.e. March 5th. Another setback!
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Amylin Pharmaceuticals, Inc.
|
|
warrsurplus |
|
23-Dec-09 12:29 pm |
| |
| 4. |
Kevin, regarding Dan Bradbury, I respectfully have to disagree. Dan has been very upfront
in all of his cc's, and without a doubt he is holding
his tongue on many issues because he doesn't want
to get on the badside of the FDA. What good does it
do for Bradbury to get the FDA in a revenge mode
by...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Amylin Pharmaceuticals, Inc.
|
|
warrsurplus |
|
7-Dec-09 01:39 am |
| |
| 5. |
Kevin-I completely agree with you on the 3/5/10 date! On the other hand
IMHO Lira will at the most receive an approvable letter,
which should further strengthen amln's claim to
the best drug to combat diabetes since the invention
of insulin! Regards, War
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Amylin Pharmaceuticals (AMLN)
|
|
warrsurplus |
|
7-Nov-09 11:46 am |
| |
| 6. |
Since amln didn&&39;t reveal obesity numbers this week, IMHO, they will
come out next week for sure. Takeda probably wanted
some lead time prior to the PR, and amln must surely
have the figures available for both pram/lep and dav
at the present time, they will be highly...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Amylin Pharmaceuticals (AMLN)
|
|
warrsurplus |
|
6-Nov-09 07:39 pm |
| |
| 7. |
I for one thought that Phase II results would have been
published before a partnership was announced. That
being said, kevinmik, I agree with you that Takeda
has obviously seen the results, and...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Amylin Pharmaceuticals (AMLN)
|
|
warrsurplus |
|
3-Nov-09 10:17 pm |
| |
| 8. |
After reading the full Takeda announcement, I think
that kevinmik is absolutly correct when he stated that
in his opinion that it is a potential 2 Billion deal,
as opposed to 1 Billion dollars. If that's the
case, Takeda has to...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Amylin Pharmaceuticals (AMLN)
|
|
warrsurplus |
|
3-Nov-09 11:13 am |
| |
| 9. |
IMO obesity news will be forthcoming either this
week or next, and I think that the results will be
astounding, in comparison to what the Phase III competitors
have already announced. If pram/lep can obtain a 16-18%
wt. loss in 56...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Amylin Pharmaceuticals (AMLN)
|
|
warrsurplus |
|
3-Nov-09 10:20 am |
| |
| 10. |
Its pretty easy to spot the shorties on
the message board. What the naysayers are forgetting
is that amln is now poised to receive almost certain
LAR approval in March, a timetable that some anal
ysts...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Amylin Pharmaceuticals (AMLN)
|
|
warrsurplus |
|
1-Nov-09 01:08 am |
| |
| 11. |
Monotherapy and pancreatic update are compelling news for
an increase in scripts, and should forge a birght outlook
going forward for amln! Hopefully positive obesity
news will be released in November, and this combination,
as well as mono and label update...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Amylin Pharmaceuticals (AMLN)
|
|
warrsurplus |
|
31-Oct-09 01:43 pm |
| |
| 12. |
Phase II on pram/lep and davin. will surely provide
an instant pop to amln's pps. If 28 week data on
pram/lep showed such a robust wt. loss, than the 56
week data will demonstably exceed any numbers that
the Phase III competitors...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Amylin Pharmaceuticals (AMLN)
|
|
warrsurplus |
|
30-Oct-09 12:48 pm |
| |
| 13. |
Haven&&39;t posted in a while but wanted to give my two cents
worth. It looks like amln is holding back making any
crucial announcements re: obesity partner until FDA
gives monotherapy approval and resolves pancraeat
ic...
Business & Finance > Investments > Stocks (A to Z) > Stocks A >
Amylin Pharmaceuticals (AMLN)
|
|
warrsurplus |
|
30-Oct-09 10:30 am |
| |